Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Stoke Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Stoke Therapeutics's regulatory disclosures and financial reporting.
Stoke Therapeutics, Inc. director Seth Loring Harrison reported 16 bona fide gift transfers on July 16, 2026, moving stock options over 303,190 underlying common shares from his direct holdings to the East Pillar 2026 Irrevocable Trust. The options are fully vested, with exercise prices between $10.90 and $40.37 and expirations from 2029 to 2036. The gifts were made for no consideration and are exempt from short-swing profit liability under Rule 16b-5.
Stoke Therapeutics, Inc. reported that Chief Scientific Officer Thomas McCauley received a grant of stock options covering 225,000 shares of common stock at an exercise price of $29.91 per share, expiring on July 14, 2036. The option vests as to 1/4 of the award on July 15, 2027, and as to 1/48 of the award monthly thereafter, subject to his continued service.
Stoke Therapeutics, Inc. reports that Thomas McCauley, its Chief Scientific Officer, is an executive officer but not a director or 10% owner. This is an initial statement of insider status and, in the data provided, does not list any specific stock transactions or derivative positions.
Stoke Therapeutics Chief Medical Officer Barry Ticho reported open‑market sales of company stock. On July 1, 2026, he sold a total of 7,228 shares of Common Stock in two transactions.
The first sale covered 6,728 shares at a weighted average price of $32.615 per share, and the second sale covered 500 shares at a weighted average price of $33.2678 per share. The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025, indicating they were pre‑scheduled rather than discretionary.
Issuer filed a Form 144 notice relating to proposed sales and recent 10b5-1 transactions in the issuer's common stock. The filing lists 7,228 restricted stock units dated 03/15/2026 as securities to be sold. It also records 10b5-1 sales of 1,795 shares for $54,891.10 on 06/01/2026 and 2,243 shares for $73,547.97 on 05/01/2026.
Stoke Therapeutics reported completion of enrollment of 162 patients in its pivotal Phase 3 EMPEROR study of zorevunersen for Dravet syndrome across the U.S., U.K. and Japan. This late-stage trial will measure change in major motor seizure frequency at Week 28, with full analysis over 52 weeks.
About 50 patients have already reached 28 weeks of treatment, and an additional cohort of roughly 30 patients in Europe is still enrolling, with the last patient expected in August. Stoke plans to begin a rolling U.S. New Drug Application submission in the first quarter of 2027, aiming to complete it in the second half of 2027 after an anticipated Phase 3 data readout in the third quarter of 2027.
Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported an open-market sale of Common Stock. On June 16, 2026, he sold 1,457 shares at a price of $29.95 per share. Following this transaction, he directly holds 18,086 shares of Common Stock. The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025, indicating the trade was made under a pre-arranged schedule rather than as a discretionary market-timing decision.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 disclosing insider sales by Jonathan Allan under a 10b5-1 plan. The filing lists dispositions of 9,293, 9,293, 4,628 and 4,267 shares on 03/20/2026, 03/20/2026, 03/18/2026 and 03/17/2026, with cash amounts shown for each trade. The filing also references Restricted Stock Units dated 03/15/2026.
Stoke Therapeutics director Arthur Tzianabos received a grant of options for 17,786 shares of common stock. The Director Stock Option has an exercise price of $29.46 per share and expires on June 2, 2036. It will vest in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, subject to his continued service.
Stoke Therapeutics director Julie Smith received a new stock option grant. On June 3, 2026, she was awarded options covering 17,786 shares of common stock at an exercise price of $29.46 per share. The options vest in full on June 3, 2027 or the date of the next annual stockholder meeting, subject to her continued service, and expire on June 2, 2036.